IN VITRO POINT-OF-CARE ASSAY METHOD/PROCESS USING COMBINATION OF BIOACTIVATED NON-MAGNETIC AND MAGNETIC QUANTUM DOTS FOR RAPID IMMUNO-OPTOMAGNETIC DETECTION OF SERUM BIOMARKERS IN FREE SOLUTION
Number of patents in Portfolio can not be more than 2000
United States of America
Stats
-
N/A
Issued Date -
Jan 16, 2025
app pub date -
Dec 30, 2021
filing date -
Dec 30, 2021
priority date (Note) -
Published
status (Latency Note)
Importance
Abstract
A method for detecting risk biomarkers for chronic neurodegenerative disorder of central nervous system called Alzheimer's disease (AD) is provided. AD is the most common cause of dementia, and it is characterized by extracellular senile plaques formed by the accumulation of amyloid β (Aβ) proteins and aggregation of tau proteins into intracellular neurofibrillary tangles in central nervous system. The present invention aims at developing a novel PoC based multiple AD biomarkers detection assay and method, such as Aβ1-40/Aβ1-42, tau protein and BDNF using multi-colored highly luminescent, non-photo-bleaching quantum dots (QDs), which provides an affordable and accurate means for early diagnosis of MCI, AD or dementia at homes, hospitals or near the patient bedsides.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully